BioCryst Pharmaceuticals, Inc. Share Price
Stocks
BCRX
US09058V1035
Biotechnology & Medical Research
|
Market Closed -
Nasdaq
21:00:00 23/10/2026 BST
|
5-day change | 1st Jan Change | ||
| 7.650 USD | -1.67% |
|
-1.80% | -1.92% |
| Market Cap | 1.95B 1.75B 1.61B 1.46B 2.73B 186B 2.78B 19.41B 7.68B 97.23B 7.34B 7.18B 307B | P/E 2026 * |
-3.31x | P/E 2027 * | 11.3x |
|---|---|---|---|---|---|
| Enterprise Value | 2.07B 1.85B 1.71B 1.55B 2.9B 197B 2.95B 20.58B 8.15B 103B 7.78B 7.61B 325B | EV / Sales 2026 * |
2.92x | EV / Sales 2027 * | 2.51x |
| Free-Float |
94.69% | Yield 2026 * |
-
| Yield 2027 * | - |
| Markets | Quality | ||
|---|---|---|---|
Nasdaq
| BCRX | Delayed | |
CBOE
| BCRX | Real-time | |
|
Mexican S.E.
| BCRX * | End-of-day quote | |
|
Tradegate
| BO1 | Real-time | |
|
Boerse Muenchen
| BO1 | Real-time | |
|
Deutsche Boerse AG
| BO1 | Delayed | |
|
Börse Stuttgart
| BO1 | Delayed | |
|
Berne S.E.
| BO1 | End-of-day quote |
Last Transcript: BioCryst Pharmaceuticals, Inc.
| 1 day | -1.67% | ||
| 1 week | -1.80% | ||
| Current month | -8.16% | ||
| 1 month | -10.21% | ||
| 3 months | -18.09% | ||
| 6 months | -14.43% | ||
| Current year | -1.92% |
| 1 week | 7.52 |  | 8.13 |
| 1 month | 7.52 | | 8.66 |
| Current year | 6.23 | | 11.22 |
| 1 year | 6.23 | | 11.22 |
| 3 years | 4.03 | | 11.31 |
| 5 years | 4.03 | | 19.99 |
| 10 years | 1.38 | | 19.99 |
| Manager | Title | Age | Since |
|---|---|---|---|
Charles Gayer
CEO | Chief Executive Officer | 55 | 31/12/2025 |
Babar Ghias
DFI | Director of Finance/CFO | 47 | 06/07/2025 |
Sandeep Menon
CTO | Chief Tech/Sci/R&D Officer | 51 | 05/04/2026 |
| Director | Title | Age | Since |
|---|---|---|---|
Jon Stonehouse
BRD | Director/Board Member | 65 | 31/12/2006 |
Theresa Heggie
BRD | Director/Board Member | 64 | 02/12/2018 |
Charles Gayer
BRD | Director/Board Member | 55 | 31/12/2025 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | Importance |
|---|---|---|---|---|---|---|
| 31/08/26 | Free | Director | 644 | 0.0003% | ||
| 31/08/26 | Free | Director | 644 | 0.0003% | ||
| 31/08/26 | Free | Director | 1,288 | 0.0005% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -1.67% | -1.80% | +6.25% | +34.21% | 1.95B | |
| +2.41% | +0.29% | +39.41% | +72.14% | 64.69B | |
| -0.15% | +7.50% | +11.42% | +71.27% | 54.78B | |
| +0.57% | +4.60% | +7.71% | +90.93% | 53.49B | |
| +0.37% | +4.67% | +26.68% | +49.64% | 45.98B | |
| -1.21% | +2.32% | +21.50% | +118.33% | 42.94B | |
| -0.37% | +5.07% | +243.23% | +789.58% | 40.08B | |
| +0.05% | +0.21% | +18.06% | +48.50% | 33.52B | |
| +1.19% | -4.98% | +26.31% | -0.76% | 23.97B | |
| -0.38% | +5.68% | +38.39% | +28.35% | 23.67B | |
| Average | +0.08% | +1.99% | +43.90% | +130.22% | 38.51B | |
| Weighted average by Cap. | +0.38% | +2.71% | +45.82% | +142.29% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 710M 634M 586M 531M 993M 67.41B 1.01B 7.05B 2.79B 35.32B 2.66B 2.61B 111B | 736M 658M 608M 551M 1.03B 69.91B 1.05B 7.31B 2.89B 36.63B 2.76B 2.7B 115B |
| Net income | -582M -520M -480M -435M -814M -55.23B -827M -5.78B -2.29B -28.94B -2.18B -2.14B -91.24B | 175M 156M 144M 131M 245M 16.62B 249M 1.74B 688M 8.71B 657M 643M 27.46B |
| Net Debt | 118M 105M 97.27M 88.15M 165M 11.19B 168M 1.17B 463M 5.86B 443M 433M 18.49B | -109M -96.89M -89.51M -81.12M -152M -10.3B -154M -1.08B -426M -5.4B -407M -399M -17.01B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 23/10/26 | US$7.650 | -1.67% | 2,745,649 |
| 22/10/26 | US$7.780 | +0.39% | 4,805,912 |
| 21/10/26 | US$7.750 | -2.39% | 5,034,035 |
| 20/10/26 | US$7.940 | -1.61% | 8,455,132 |
| 19/10/26 | US$8.070 | +3.59% | 9,774,412 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- BCRX Stock
Select your edition
All financial news and data tailored to specific country editions
